Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with extensive-stage small cell lung cancer that progressed on or after platinum-based chemotherapy.
LAMPGEN ANALYSIS
Why it matters
The DLL3-directed T-cell engager introduced a different treatment approach after platinum chemotherapy. The 2024 action was accelerated. The FDA granted traditional approval in November 2025.
What research teams should watch
Design step-up visits around the observation requirements, with clear plans for cytokine release syndrome and neurologic changes.
PRIMARY RECORDS